ΑΘΑΝΑΤΕ ΜΑΥΡΟΓΙΑΛΟΥΡΕ

FDA approves Votrient to treat kidney cancer.

Dow Jones Newswire (10/20, Dooren) reports that the FDA on Monday approved GlaxoSmithKline PLC's Votrient (pazopanib) to treat kidney cancer. Votrient is the sixth drug to be approved since 2005 to treat kidney cancer, and the FDA said the drug appears to work equally as well as Pfizer's Sutent [sunitinib malate] and Nexavar [sorafenib]. The FDA also said doctors need to monitor liver function before and during treatment with Votrient, and that patients receiving it should also receive periodic electrocardiograms to monitor for heart rhythm abnormalities.